...
首页> 外文期刊>Homeopathy: the journal of the Faculty of Homeopathy >Homeopathic treatment in addition to standard care in multi drug resistant pulmonary tuberculosis: A randomized, double blind, placebo controlled clinical trial
【24h】

Homeopathic treatment in addition to standard care in multi drug resistant pulmonary tuberculosis: A randomized, double blind, placebo controlled clinical trial

机译:顺势疗法除了多种药物抗性肺结核的标准护理外:一项随机,双盲,安慰剂控制临床试验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Multi drug resistant-tuberculosis (MDR-TB) [resistant to Isoniazid and Rifampicin] is a major global public health problem. In India the incidence is rising in spite of implementation of Revised National Tuberculosis Control Program. Standard MDR-TB drugs are second generation antibiotics taken for 24-27 months. The present study was undertaken to evaluate the efficacy of add on homeopathic intervention to the standard MDR-TB regimen (SR). Methods: A randomized, double blind, placebo controlled study was conducted from 2003 to 2008. 120 diagnosed MDR-TB patients (both culture positive and negative) were enrolled and randomized to receive Standard Regimen+individualized homeopathic medicine (SR+H) or Standard Regimen+identical placebo (SR+P). The medicines have been used in infrequent doses. The outcome measures were sputum conversion, changes in chest X-ray (CXR), hemoglobin, erythrocyte sedimentation rate (ESR), weight gain, and clinical improvement. Results: There was an improvement in all the outcome measures as per intention to treat (ITT) and per protocol (PP) analyses. ITT analyses revealed sputum culture conversion from positive to negative in 23 (38.3%) in SR+H; 23 (38.3%) patients in SR+P group; (p=0.269) and 27 (55.1); 21 (42.8%), p=0.225 as PP analyses. The mean weight gain in SR+H group was 2.4±4.9 and in SR+P was 0.8±4.4; [p=0.071], reduction in ESR in SR+H was -8.7±13.2; SR+P was 3.9±15.4 [p=0.068]. The mean increase in hemoglobin was by 0.6±1.7 in SR+H & 0.3±2.3 [p=0.440] in SR+P group at 95% confidence interval. Statistically significant improvement was seen in CXR in 37 (61.7%) in SR+H and 20 (33.3%) patients in SR+P group (p=0.002).Subgroup analyses of culture positive patients showed statistically significant improvement in CXR (p=0.0005), weight gain (p=0.026), increase in hemoglobin (p=0.017) and reduction in ESR (p=0.025) with add on homeopathy. The cure rate was 11.4% more in SR+H group as compared to placebo group. Change in sputum culture conversion, was not statistically significant. Conclusion: Add on homeopathy in addition to standard therapy appears to improve outcome in MDR-TB. Larger scale studies using a standardized homeopathic treatment regime should be conducted.
机译:背景:多抗药性 - 核核(MDR-TB)[对异烟肼和利福平的抗性]是全球的主要公共卫生问题。在印度,尽管实施了修订的国家结核病控制计划,但发病率仍在上升。标准MDR-TB药物是第二代抗生素24-27个月。本研究的目的是评估标准MDR-TB方案(SR)的ADK ADGE添加干预的功效。方法:从2003年到2008年进行了一项随机,双盲,安慰剂对照研究。有120名被诊断的MDR-TB患者(培养物阳性和阴性)被纳入并随机接受标准方案+个性化的顺势疗法(SR+H)或标准方案+相同的安慰剂(SR+P)。这些药物已用于不经常剂量。结果度量是痰液转化,胸部X射线(CXR)的变化,血红蛋白,红细胞沉降率(ESR),体重增加和临床改善。结果:根据治疗意图(ITT)和根据方案(PP)分析,所有结果指标都有改善。 ITT分析显示,SR+H中23(38.3%)的痰液培养物转化为23(38.3%)。 SR+P组的23(38.3%)患者; (p = 0.269)和27(55.1); 21(42.8%),p = 0.225作为PP分析。 SR+H组的平均体重增加为2.4±4.9,SR+P中的平均体重增加为0.8±4.4; [P = 0.071],SR+H中ESR的减少为-8.7±13.2; SR+P为3.9±15.4 [P = 0.068]。 Sr+H&0.3±2.3 [p = 0.440]在95%置信区间中,血红蛋白的平均增加为0.6±1.7 [p = 0.440]。在SR+H的37例(61.7%)中,CXR中有统计学显着改善,SR+P组的患者为20(33.3%)(33.3%)(p = 0.002)。培养阳性患者的分析表现出CXR的统计学显着改善(P = P = 0.0005),体重增加(P = 0.026),血红蛋白增加(P = 0.017)和ESR的减少(P = 0.025),并加上顺势疗法。与安慰剂组相比,SR+H组的治疗速率在SR+H组中高出11.4%。痰培养转化的变化在统计学上没有显着意义。结论:除了标准疗法外,还可以增加顺势疗法,从而改善了MDR-TB的预后。应使用标准化顺势疗法治疗方案进行大规模研究。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号